Baader Bank set a €19.00 ($22.35) target price on MediGene AG (ETR:MDG1) in a research report report published on Thursday morning. The firm currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on the stock. Oddo Securities set a €13.00 ($15.29) price objective on shares of MediGene AG and gave the stock a buy rating in a research report on Monday, May 29th. Independent Research GmbH set a €12.00 ($14.12) target price on shares of MediGene AG and gave the stock a neutral rating in a research report on Monday, May 29th.

MediGene AG (ETR:MDG1) opened at 10.23 on Thursday. The stock has a 50 day moving average of €11.01 and a 200 day moving average of €11.81. The company’s market cap is €206.11 million. MediGene AG has a 52 week low of €6.63 and a 52 week high of €15.19.

ILLEGAL ACTIVITY NOTICE: “MediGene AG (MDG1) Given a €19.00 Price Target at Baader Bank” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/medigene-ag-mdg1-given-a-19-00-price-target-at-baader-bank.html.

MediGene AG Company Profile

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.

Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.